Rare disease drug safety tracked in tiny french study
NCT ID NCT06949358
First seen Apr 14, 2026 · Last updated May 23, 2026 · Updated 5 times
Summary
This study followed 3 people with acid sphingomyelinase deficiency (ASMD) who had already completed earlier studies of the enzyme replacement therapy olipudase alfa. The goal was to monitor safety and side effects while providing the drug until it was officially covered in France. Participants received infusions every 2 weeks for up to 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACID SPHINGOMYELINASE DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site Number : 2500001
Paris, 75020, France
-
Investigational Site Number : 2500002
Bron, 69500, France
Conditions
Explore the condition pages connected to this study.